Q-omics provides the consensus-scored MTATP6P25 profile across patient tissues and cancer cell-line models. MTATP6P25 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MTATP6P25 is differentially expressed in 5, with the highest sampling consensus in KICH. Additionally, MTATP6P25 RNA expression shows 11,258 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KICH as cancer lineages where MTATP6P25 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTATP6P25 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTATP6P25 survival associations across molecular data types. MTATP6P25 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTATP6P25 RNA expression–survival associations across cancer types. High MTATP6P25 expression shows unfavorable associations in THYM, BRCA, LUSC and READ, but favorable associations in ACC and SKCM. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MTATP6P25 RNA expression.
This table summarizes MTATP6P25 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for MTATP6P25. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTATP6P25 shows lower tumor expression in KIRC and higher tumor expression in KICH, COAD, LIHC and LUAD. The KICH box plot shows higher MTATP6P25 RNA expression in tumor versus normal tissue (log2 FC = +0.772, t-test p = .004).
This table shows molecular features associated with MTATP6P25 in patient tissues and cancer cell lines. In patient samples, MTATP6P25 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
